Abstract
The FDA-approved schedule and dose of bevacizumab (BVZ) for recurrent glioblastoma (rGB) (10 mg/kg q 2 weeks) were adopted from systemic cancer protocols. No dose-defining studies have been performed for glioblastoma. We began using BVZ for the treatment of rGB in 2005 at the dose of 5 mg/kg every 2 weeks combined with irinotecan, and later as single agent. Our previous report of 20 patients treated with BVZ 5 mg/kg every 2 weeks showed similar response rates and overall survival (OS) compared to other BVZ treatment protocols, with less adverse effects. In this study we retrospectively reviewed our 7 year experience with BVZ in 162 rGB patients. Treatment outcomes were analyzed from 87 patients who received BVZ at 5 mg/kg and 75 patients at 10 mg/kg. While median age was similar in both groups, the median KPS was significantly higher in the group treated with 10 mg/kg BVZ (85 versus 60). There was no significant difference in OS or progression free survival (PFS) between the groups treated with BVZ 5 versus 10 mg/kg. Overall survival was significantly improved in the subgroup treated with cytotoxic therapy in addition to BVZ 10 mg/kg. There were more adverse events seen with BVZ 10 mg/kg. There is no significant difference in OS for rGB treated with BVZ 5 mg/kg versus 10 mg/kg when given as monotherapy. The smaller dose was slightly less toxic. Addition of cytotoxic therapy resulted in prolongation of OS in a small subgroup of BVZ 10 mg/kg.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12(3):356–361
Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6):713–718
Summers J, Cohen MH, Keegan P, Pazdur R (2010) FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 15(1):104–111
Rose S (2011) FDA pulls approval for Avastin in breast cancer. Cancer Discov 1(7):1–2
Bokstein F, Shpigel S, Blumenthal DT (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112(10):2267–2273
Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 7:Abstract 369
Stupp R, Mason WP, Bent MJ et al (2005) European organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28(12):e188–e189
Lu J-F, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779–786
Gaudreault J, Bruno R, Kabbinavar F, Sing A, Johnson DH, Lu J (2004) Clinical pharmacokinetics of bevacizumab (Avastin®) following every 2-or 3-week dosing. J Clin Oncol 23:205
Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60–65
Chong G, Tebbutt NC (2010) Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2(5):309–317
Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019
Van Cutsem E, Rivera F, Berry S et al (2009) First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847
Yildiz R, Benekli M, Ozkan M et al (2012) Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. J Cancer Res Clin Oncol 138(11):1845–1852
Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191
Escudier B, Pluzanska A, Koralewski P et al (2007) AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111
Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth receptor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434
Pujade-Lauraine E, Hilpert F, Weber B (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302–1308
Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740
Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745
Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S (2011) Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 9(4):403–407
Levin VA, Mendelssohn ND, Chan J et al (2015) Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neuroncol 122(1):145–150
Taal W, Oosterkamp HM, Walenkamp AM et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953
Wick W, Brandes AA, Gorlia T, et al. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial. Neuro Oncol (2015) 17 (suppl):v1, Abstract LB-05. Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology, November 19–22, 2015, San Antonio, Texas
Zhong J, Ali AN, Voloschin AD et al (2015) Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer 121(9):1456–1462
Seet RC, Rabinstein AA (2012) Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 105(1):69–75
Aldape K, Zadeh G, Mansouri S, Reifenberger G, Deimling A (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):829–848
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There are no conflicts of interest from any of the authors.
Additional information
Precis for table of contents
Bevacizumab 5 mg/kg as monotherapy for the treatment of recurrent glioblastoma may be equivalent to the dose of 10 mg/kg, with less toxicity. Addition of cytotoxic therapy may benefit a subgroup of these patients.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Blumenthal, D.T., Mendel, L. & Bokstein, F. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?. J Neurooncol 127, 493–502 (2016). https://doi.org/10.1007/s11060-015-2025-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-015-2025-5